Which companies overlap with Institut National de la Santé Et de la Recherche Médicale, France's portfolio?

Top competitors by shared drug class: The University of Hong Kong, GlaxoSmithKline, Protein Sciences Corporation, Tan Tock Seng Hospital, Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/institut-national-de-la-sant-et-de-la-recherche-m-dicale-france.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Institut National de la Santé Et de la Recherche Médicale, France — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Institut National de la Santé Et de la Recherche Médicale, France pipeline: 3 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
curcuma longa	curcuma longa	marketed
Anti-H1N1v Vaccine	Anti-H1N1v Vaccine	marketed	Inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens	Immunology / Infectious Disease
Rapamycin	Rapamycin	marketed		Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2	Oncology
Bilhvax vaccine (Sh28GST)	Bilhvax vaccine (Sh28GST)	phase 3	Recombinant protein vaccine	Sh28GST (Schistosoma haematobium 28 kDa glutathione S-transferase)	Infectious Disease / Parasitology

Therapeutic area mix

Other · 2
Immunology / Infectious Disease · 1
Infectious Disease / Parasitology · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

The University of Hong Kong · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Protein Sciences Corporation · 2 shared drug classes
Tan Tock Seng Hospital · 2 shared drug classes
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 2 shared drug classes
Chiltern Pesquisa Clinica Ltda · 1 shared drug class
Brigham and Women's Hospital · 1 shared drug class
BiondVax Pharmaceuticals ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Institut National de la Santé Et de la Recherche Médicale, France:

Cite this brief

Drug Landscape (2026). Institut National de la Santé Et de la Recherche Médicale, France — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/institut-national-de-la-sant-et-de-la-recherche-m-dicale-france. Accessed 2026-05-16.